UPDATE 1-Antigenics up as Glaxo vaccine trials use co's adjuvant

* Glaxo starts last-stage trials for shingles vaccine

* Antigenics Shares up 20 pct

Aug 25 (Reuters) - Antigenics Inc AGEN.O said its vaccine adjuvant was a key component in GlaxoSmithKline Plc's GSK.L experimental shingles vaccine that started final stage trials recently, sending the U.S. biotechnology company's shares up as much as 20 percent.

Glaxo plans to study more than 30,000 patients globally for shingles, a viral disease that results in painful rash on one side of the body with limited current treatment options.

An adjuvant helps boost the immune system response, requiring less quantity of vaccine in each dose.

Antigenics' experimental adjuvant QS-21 is being tested in nearly 20 indications, including Johnson & Johnson's JNJ.N potential treatment for Alzheimer's disease.

“This adjuvant has substantial revenue potential for Antigenics with no associated developments costs to the company,” Antigenics’ Chief Executive Garo Armen said in a statement.

The Lexington, Massachusetts-based company’s shares, which have lost 63 percent of their value over the past one year, were up 10 percent at 85 cents in late afternoon trade Wednesday on Nasdaq. They touched a high of 94 cents earlier in the session.

More than 2.5 million shares were traded by 1547 ET, nearly 10 times their 10-day average volume. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Vinu Pilakkott)


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.